drugset / Trial / NCT02182856

Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD

NCT02182856

Phase 4 Completed 33 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen saturation (SaO2) and to characterise patients with COPD (chronic obstructive pulmonary disease) at risk of significant arterial oxygen desaturation following nebulised salbutamol.

Timeline

Start
1998-02
Primary completion
2000-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule 500 ug Inhaled
Subject Salbutamol Unknown 3 mg Inhaled
Subject Salbutamol Unknown 6 mg Inhaled